Quick Answer
Dare Bioscience, Inc. reported Revenue (ASC 606) of $1.03 million for fiscal year 2025.
Dare Bioscience, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $1.03M | +10429.4% |
| 2024 | $9.8K | -99.7% |
| 2023 | $2.81M | -71.9% |
| 2022 | $10.00M | — |
| 2021 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.3K | -94.6% | -91.1% |
| March 31, 2025 | $25.4K | +173.3% | -39.0% |
| September 30, 2024 | $41.7K | -95.8% | +85.8% |
| June 30, 2024 | $22.4K | — | +141.2% |
| March 31, 2024 | $9.3K | — | -99.1% |
| September 30, 2023 | $1.00M | — | — |
| June 30, 2023 | $0.00 | -100.0% | — |
| March 31, 2023 | $0.00 | — | — |
- Dare Bioscience, Inc. showed an increase of +10429.4% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from Dare Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: